Reports Q2 revenue $261.4M, consensus $242.1M. “We had another strong quarter in which we served over 600,000 patients, delivered significant year-over-year growth in volumes and revenues, drove improvements in gross margin and reduced our quarterly cash burn,” said Steve Chapman, Natera’s Chief Executive Officer. “With this excellent performance, we are raising our annual revenue guidance and believe we are well-positioned to meet our financial goals for the year. Looking ahead, we have a robust clinical pipeline, particularly in oncology, that we believe will further differentiate our products and change the standard of care for millions of patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- Natera files patent infringement suit against NeoGenomics
- Natera completes enrollment in ALTAIR trial
- Craig-Hallum says CareDx appears to look to Congress for help amid Castle reversal
- CareDx announces district court upholds March 2022 jury verdict against Natera
- Natera announces ruling in favor of the company in CareDx false advertising case